HOME > About Walvax > Company introduction

Get Adobe Flash player

Founded in 2001, Walvax Biotechnology Co., Ltd. (Walvax) is a leading vaccine producer, engaged in research and development, manufacturing and distribution of safe and efficacious quality vaccines. Headquartered in China’s southwestern city Kunming in Yunnan Province, Walvax went to IPO in 2010 (300142.SZ) and started business expansion from traditional vaccines to innovative vaccines. With the vision of dedicating to be the pride domestically and the pioneer globally in the vaccine industry, producing efficacious, quality, innovative and affordable products to protect people from the world’s deadliest diseases, Walvax’s purpose is to help everyone live a healthy life.

Walvax has assembled a seasoned core management team consisting of entrepreneurial teams from CNBG and senior vaccine experts from MNCs, as well as 10 senior overseas returnee scientists and over 100 doctor's or master's degree personnel.

In the research and development area, Walvax has two independent subsidiaries: one is Shanghai Zerun Biotechnology Co., Ltd. (Zerun) in Shanghai’s Medicine Valley Zhangjiang, Pudong; the other is Walvax Technical Center in Kunming’s Hi-Tech District. Led by west-trained scientists and vaccine experts, Zerun is working on recombinant virus-based vaccines, with its bi-valent human papillomavirus vaccine (HPV-2) which has filed BLA application and nona-valent HPV vaccine (HPV-9) which is going to complete Phase I trial. On the other hand, Walvax Technical Center, dedicated to developing bacteria-based vaccines, has successfully developed 7 licensed vaccines (9 presentations), including recently approved 13-valent pneumococcal conjugate vaccine (PCV13-TT), one of the most difficult vaccines to develop in the world. 

To date, Walvax has three manufacturing facilities in Yuxi City, Yunnan, Daxing District, Beijing and Taizhou City, Jiangsu, respectively. Located in Yuxi City which is about 40 miles (70 km) south of Kunming, Walvax's commercial manufacturing facility of 130,000 m² floor space is currently manufacturing all licensed and to be licensed vaccines, such as HPV-2. The annual capacity for a variety of vaccines at Yuxi facility is about 190 million doses a year.

Walvax covers markets in 2400 counties among 30 provinces in China. As of today, Walvax manufactures and distributes 13-valent pneumococcal polysaccharide conjugate vaccine, haemophilus influenza type b conjugate, group A and C meningococcal polysaccharide, group A and C meningococcal conjugate, group ACYW135 meningococcal polysaccharide (MPV ACYW135), 23-valent pneumococcal polysaccharide and DTaP vaccines in China. Beyond China, Walvax has worked closely with business partners to reach overseas markets on the Belt and Road, and has been exporting vaccines to 15 countries, including Indonesia, Egypt, the Philippines, Bangladesh, Guinea, Nigeria, Senegal, Mauritius, Niger, India, Kyrgyzstan, etc.

In the global collaboration area, Walvax and its subsidiaries have been partnering with academic institutions, industry peers and international organizations. To date, Walvax has received three grants with US$ 8.5 million in total during the last 6 years from the Bill & Melinda Gates Foundation to support WHO prequalification for the HPV-2 and HPV-9 in order to prepare for UNICEF procurement for Gavi countries, and to expedite pre-clinical research of Recombinant SARS-CoV-2 Vaccine as well. In addition, several other vaccines, including PCV13-TT and MPV ACYW135, are also under PQ preparations.